Post Reply
8641-8660 of 10899
BENGSETR, I AM WITH YOU, LONGTERM! ENOUGH SAID!
Wah.. my message from my other manifestation (just prior to my last posting) got deleted from the forum so fast. So sorry if you missed the point...
Could have breached the T&Cs of this site..
Hey, do I know you?
Anyway?Oh poor you..! I really sympathize with you. You should not have listened to them. Should have followed my other half?s call??ha ha ha ha ha <laughter with alot of cynicism>
BTW, I like your nick.
PS: meaning of SockPuppet
Taken from Wikipedia
A sockpuppet is an online identity used for purposes of deception within an Internet community. In its earliest usage, a sockpuppet was a false identity through which a member of an Internet community speaks while pretending not to, like a puppeteer manipulating a hand puppet.[1]
In current usage, the perception of the term has been extended beyond second identities of people who already post in a forum to include other uses of misleading online identities. For example, a NY Times article claims that "sock-puppeting" is defined as "the act of creating a fake online identity to praise, defend or create the illusion of support for one?s self, allies or company."[2]
The key difference between a sockpuppet and a regular pseudonym (sometimes termed an "alt") is the active exploitation of the pretense that the puppet is a third party who is not affiliated with the puppeteer. Using multiple identities for privacy purposes (for example, one identity divulges information which is easily identifiable and the other identity acts as a whistleblower) is not considered sockpuppetry unless one identity expresses assent to another identity's posting.
Hi allright.. tks for the compliment but i m not as good as many here.. me oni got good network thru yrs of experience and in pharma/bio industry.
In terms of TA.. cashiertan is one good adviser.. Bengster and cwwan1 is one good information providers, investor is one good analyzer..
Hi cyjjerry85.. based on DJ performed on Fri.. it might b a good day to short in Most counters... it depends u r Short or doin Naked Short.. Naked Short might b risky.. cos CE might b any moment.. (haha.. but i m not issue it..so i dun noe which date hor.. )
for those who had loss money in tis counter, i m sorry to hear tat.. In trading.. u either win or u loss.. if u choose to invest just bcos someone painted a good pic in tis forum (eg.. me lor) and later sell bcos someone keep hinting T+3, etc.. pls dun flame anyone.. learn to accept your own mistake since no one pointed any gun on your head to buy/sell.
Thanks cwwan for the reports and Bengster for the clear explanation . Please NOTE WE MAKE our own decision based on what you and fellow forumers have posted. Cashiertan did say to watch for .95cts etc and the technicals behind it . Further the whole market was truly bad on Friday. Actually pension if you just advise us to take profit at certain levels like Huatah and cashiertan based on trends or the fact that we have made $ , I would have said you were genuine. But you kept on mocking at every turn even when the shares went up .Your last posting sounded very logical and I was glad until you ended with 'hahahaha' You mean you are happy people lost money? So why are those who lost money cursing at bengster? It should be you because you added so much confusion . So behave Pension . You can value add and as bernie posted, let us get back to being serious and giving clear advice. Yes , shares go up and down . With BIG the potential is there and the true investors are in for the eventual (with the knowledge of risks like further delays etc..)All pointed out by Bengster and the recent reports by analysts. I may be new but i am NOT YOUNG and am a PROFESSIONAL with a thriving practice. I went into this share because a friend needed a stent put in and i did my research and came upon this forum.I was impressed by what has been logically pointed out as the potential . But I also read that I should NOT chase a soaring stock which as a human I did at .885. Totally my fault.So let's hope for the best ok and hope the BIG gets the long awaited CE mark by late Jan 2008
A BIG kam siah to fellow forumers that appreciate my postings. I think the US$45m convertible loan stock has an average conversion price of $1.05 per share. I would also like to clarify why some articles put JNJ acquisition of Conor at US$1.3B, some put it at US$1.4B. The difference is the US$100m cash in hand that Conor was holding during takeover time. So it is a difference of including or excluding the cash holding for takeover valuation. But strictly speaking, it should be US$1.4B.
As for the "any limus drug on biodegredable polymer", so far BIG has not sued any other DES players yet. JWMS is the only DES player selling limus drug on biodegredable polymer with regulatory approvals and with BIG's blessing. Of course BIG can choose to sue JWMS earlier for patent breach to stop EXCEL's sales.... OR to extract out lucrative lump sum payment plus royalty on sales. However, JWMS now is a subsidiary of BIG so BIG is allowing JWMS to has access to this patent.
However, there are several other small new comer DES players using limus drugs on biodegredable polymer. Abbott's ABSORB DES also uses a limus on biodegredable polymer. These companies will one day be at the mercy of BIG for patent breach once their DES is approved for sale. BIG will come after them via worldwide injunction to stop their DES sales via patent breach or extract out lucrative payment/royalties from them. BIG is still a small company and normally under such circumstances, money can solve such patent breach issue (win-win strategy). If BIG is bought over by say JNJ, those DES players in breach of this limus drug on biodegredable polymer patent can forget abt commercialising their DES. JNJ has over US$10 billion of cash and don't need their royalties. JNJ want to eliminate all other rivals and become the most dominant DES player and will never allow this patent to be breached by others. The DES industry knows that limus family of drugs is the best stent drug and biodegredable polymer has great potential to address late-thrombosis issue (a very critical problem for DES). The industry is heading towards limus drugs on biodegredable polymer. This is the potential of how powerful BIG's patent cab really be. This patent can be the "King Maker" in the DES industry. Takeover buyers will "lao chwee nuah" over this key patent that BIG is holding. It is a very powerful patent weapon to elinimate other DES rivals.
Jinsong (Jin) Du
Research Analyst
CREDIT SUISSE
We suspect Shandong Weigao sold out due to the partnership with Medtronic
Shandong Weigao recently formed a partnership with Medtronic (MDT, $49.40, Neutral, TP $52.00), which also has a stent business. We believe this could be one of the key reasons for Shandong Weigao to sell out its stake in JW Medical. We also draw comfort from the fact that Shandong Weigao agreed to settle the transaction in Biosensors shares instead of cash, which we believe shows confidence in Biosensors' future.
To: Jinsong Du
*** No need to suspect. Why would BIG allow a stent rival Medtronic to have access to this limus drug on biodegredable polymer for free? This JWMS acquisition is made possible because of BIG's patent. It is a win-win solution, though more advantages for BIG in this JW deal. If Weigao and Medtronic is dealing with JNJ for patent breach, things will not be easy.
Drug Coated Stents Heart-Safe, Study Suggests
ScienceDaily (Jan. 12, 2008) ? Much controversy has developed over the past year about the safety and potential complications of drug-eluting heart stents, increasing the risk of possible fatal blood clots, even years after an angioplasty procedure. However, a new Canadian study led by investigators from Ontario?s Institute for Clinical Evaluative Sciences (ICES) and McMaster University?s Program for Assessment of Technologies in Health, tells a different story.
Drug-eluting stents were found to be most effective in reducing the need for repeat angioplasty procedures or bypass surgery in angioplasty patients at the ?highest risk? for a renarrowing of the artery around the stent, without significantly increasing the rate of death or risk of heart attack. Lead Author, ICES Sr. Scientist , Dr. Jack Tu says, ?This is good news, reassuring patients and cardiologists about the safety of drug-eluting stents when used in appropriate individuals. Our results also suggest physicians should be selective in using drug-eluting stents, offering them to angioplasty patients who are at the highest risk for repeat cardiac procedures.?
Reporting in the October 4, 2007 issue of the New England Journal of Medicine, the large Canadian study conducted at ICES, in collaboration with cardiologists and researchers from Sunnybrook Health Sciences Centre and the University of Toronto, looked at over 3,700 unique matched pairs of Ontario patients who received drug-eluting stents (DES) or more conventional bare metal stents (BMS) during angioplasty. Using data from the Ontario Cardiac Care Network?s (CCN) population-based angioplasty registry, and accounting for differences in patient characteristics, investigators analyzed the outcomes of patients having angioplasty in Ontario between December 2003 and March 2005 for the ?real-world? effectiveness of DES. The results:
- DES reduced the need for a second procedure to unblock or bypass a clogged artery by 30% relative to BMS, from 10.7% to 7.4%.
- After 3 years of follow up, mortality was reduced for DES patients (5.5%) relative to BMS (7.8%).
- After 2 years of follow up, rate of heart attack for DES patients was marginally but not significantly higher at 5.7% vs.5.2% in BMS patients.
- The reduction in the need for repeat procedures (i.e. target vessel revascularization [TVR rate]) was greatest in patients with two or three risk factors (e.g. diabetes, small vessels, or long lesions) for renarrowing of the artery, whereas lower and intermediate risk patients did not have significant reductions in TVR rates.
Co-Author, Dr. Eric Cohen, Medical Officer for CCN says, ?Drug-eluting stents have been at the centre of a very active worldwide debate regarding issues of safety, degree of benefit and funding of a relatively expensive new technology. This study will be very helpful to clinicians, administrators and policy-makers in clarifying these issues as it confirms that using drug-eluting stents in patients at high risk for renarrowing is both effective and safe.?
Interventional Cardiologists use the tiny wire mesh tubes called stents to help prop open narrowed arteries after angioplasty, an artery clearing operation and a common medical procedure for treating angina and heart attacks. Prior to the development of stents, more than 20% of angioplasty patients required a second angioplasty or bypass surgery because of renarrowing of their coronary arteries. Both bare metal and drug-eluting stents enable blood to flow more easily through the artery by holding it open, with drug-eluting stents also leaking drugs to prevent tissue re-growth from re-clogging the arteries.
ICES Sr. Scientist, Dr. Jack Tu who holds a Canada Research Chair in Health Services Research at Sunnybrook Health Sciences Centre and the University of Toronto, says ?Physicians implanting the devices need to ensure patients who get a drug-eluting stent also take anti-clotting medication such as aspirin and clopidogrel (antiplatelet therapy) for a minimum of one year after the angioplasty procedure. This therapy reduces the risk of fatal blood clots associated with drug-eluting stents. This prolonged period of clopidogrel usage could explain differences between results in Ontario, compared to those from other countries, such as Sweden. In our study, these medications were made available to all elderly patients in Ontario, at minimal cost, through the Ontario Drug Benefits Program for one year after the angioplasty procedure.?
Since their introduction in 2003, more than six million heart patients worldwide have received a drug-eluting stent (DES). The DES market is worth $5 billion a year, costing about $2300 for a DES versus $700 for a bare metal stent (BMS). The rate of DES use in countries like the United States was as high as 90% but dropped to about 70% in the past year, after recent controversy over safety. Recent studies from Europe and Sweden suggest DES may increase mortality and heart attack after a coronary angioplasty. The rate of DES usage in Ontario was on average 38% of all stents during the study period. In 2003, the Ontario government approved the introduction of DES provincially, conditional upon an independent evaluation of their effectiveness and cost-effectiveness. Approximately 20,000 angioplasties are performed each year in the province of Ontario.
The study ?Effectiveness and safety of drug-eluting stents in Ontario? is in the October 4, 2007 issue of the New England Journal of Medicine. The study was funded by operating grants from the Ontario Ministry of Health and Long-term Care and a Canadian Institutes of Health Research Team Grant in Cardiovascular Outcomes Research.
hm...anyone thinking of shorting this counter on Monday
This article is provided to FT.com readers by Pharmawire?a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market. www.pharmawire.com
--------------------------------------------------------------------------------------------------------
Two new drug-eluting stents expected to enter the market may be easier for surgeons to insert, but their safety and efficacy profiles will be comparable to their predecessors, physicians told Pharmawire.
These physicians added that the overall use of stents has declined, as patients are screened for their ability to comply with a long-term anticoagulant regimen.
The FDA?s Circulatory System Devices Panel last quarter recommended both Abbott?s Xience V and Medtronic?s Endeavor for regulatory approval. The FDA is not required to follow that recommendation, but typically does.
The drug-eluting stent category - which includes Cordis?s Cypher and Boston Scientific?s Taxus - came under scrutiny last year when researchers noticed an increased risk of blood clots with these devices compared to bare-metal stents.
The devices consist of three parts - the metal stent itself; a drug that prevents the artery from re-closing (restenosis); and the polymer that binds the drug to the metal, controlling its release over time.
Cardiologists note that it?s unclear whether blood clots result from an inflammatory response to the polymer, or because the attached drug delays the healing process, leaving the metal exposed in the artery for a longer period of time.
?I believe that technology will overcome these problems,? said Dr Dawn Abbott, a stent researcher and interventional cardiologist at Brown Medical School. But ?I don?t think the next generation of stents that become available to us will make a difference.?
Dr Paul Gurbel, director of the Sinai Center for Thrombosis Research, similarly responded with a resounding ?no? when asked whether the next generation of stents would overcome these problems. ?I don?t know any data that would rigorously support the use of one drug versus another,? he said.
Yet Dr Allen Jeremias, director of vascular medicine and peripheral intervention at the State University of New York, Stony Brook, noted that newer stents have ?theoretical benefits? because they are thinner and easier to insert. Endotheliazation - the aforementioned healing process - might also be quicker with a thinner stent, he added.
The devices themselves offer trade-offs, physicians note. The Endeavor stents seems to be associated with less late-stage thrombosis, but more ?late loss?, or tissue growth inside the blood vessel in the months following the procedure.
The Endeavor?s zotarolimus coating is the least potent agent for repressing restenosis, according to Jeremias.
But Dr Abbott emphasized that it?s still unclear whether these differences will translate into different clinical outcomes for patients.
Abbott noted that the use of drug-eluting stents reached its peak in 2005, when 94% of patients undergoing cardiac catheterization received them. Their usage has since fallen to about 60-70%, she estimated, largely because of greater screening procedures. ?I think there?s a greater awareness of looking at the risk-benefit ratio in individual patients,? she said.
Drug-eluting stents reduce the risk of restenosis by 50% compared to bare-metal stents; the risk of developing thrombosis is 0.2-0.4%, she added.
?The drug-eluting stents are back, but the patients are screened more carefully for their ability to take dual anti-platelet therapy,? a regimen of Plavix and aspirin, Jeremias said.
Cypher?s third-quarter sales fell more than 40% in the third quarter. Boston Scientific reported that sales of its drug-eluting stents declined about 22% in the same period.
Abbott has a market cap of USD 92.89bn. Medtronic has a market cap of 57.46bn.
Are we applying the patent on limus drug on biodegradable stent?
sorry i mean 2009 fiscal year
this for long term investor
2008 fiscal year will see BIG profit earning around 80-100m is acheviable. Bulk part of earning will come from licensing which include milestone payment and loyalties( Bensgter mention BIG have 5% in xtent and Devax and not forgetting Terumo loyalties, at zero cost purely sales) followed by JW and biomartix sales. If BIO decide to FDA in US, a good strategy is important otherwise it is costly to do the 100m trial.
Pls don't blame anybody for that. Bro bengster & others here just to give us information. It's your own money and you made your own decision. And you should be responsible for whatever decision you made.
Moreover, didn't they warn you?? - NOT AN INDUCEMENT TO BUY. BUY AT YOUR OWN RISK. NEVER CHASE A SOARING STOCK. DISCOUNT PERIOD IS OVER...
I took my profit long ago. But still prepare to go in again when suitable time comes.
Lucky, I did not load this company share. My broker advise me to stay side line until their CE is approved.
this for contra player.
when market uptrend, u can make money. when market downtrend u oso can make money. as i said, he need to go in fast, come out fast, dun be greedy and avoid keeping ur holding overnight. friday is an example, some keep over night and dow plunge, if u have listen to my call to take profit or cut loss last friday, thing will be different this monday.ha ha ha ha ha ha ha ha ha
omg, someone here and his kaki is trying to window dress, no use lah, ppl had loss money. those holding on will suffer and regret even more.
a but call or sell call HERE does not make u loose money.
You can either take his advise or not.... YOU YOURSELF is the one that make u loose money...
relax and enjoy the sea of reds
I started this thread in May 2006 and have been following Bengster's postings and doing my due diligence ever since. From his posts I have gathered that he is knowledgeable and has in-depth understanding of the industry and is sincere about its long-term value. Those forummers who wish to trade or short this counter do it at their own risks. Although a forum is a platform for everyone's views to be heard, it does not have to degenerate into a spitting gutter. I detect the exasperation in Bengster's posts and would like offer my support for all his good work thus far. If you do not believe in the intrinsic value of this share it is no use repeating your tired old arguments over and over again as people of the same mind would have been warned already. Chin up Bengster!
 x 0
 x 1
* Alert Admin |
ha ha ha ha, someone exit quietly and now talk about trigger point bla bla bla, it is too late?? if u have confident and so positive that the c/e mark approval(less than 3 weeks) will uptrend this counter, why exit?? should hold on to it to show those induced ur believe. i expect him to talk like a bull. why talk about trigger point now and not on wednesday, thursday or friday early morning 9.00am. is it too late when those induced got stuck and burn badly. come morning, worst, dun know how many newbie gonna get burn very badly. everyone here was so upset about my call to sell, this counter dun worth even 90 cents, make losses every year, no dividend pay out, high risk counter, advise u to check with ur broker bla bla bla. i am here to tell u nothing but the truth and it is ur choice to believe in me or in them. if u believe in them, u should not curse and swear, juz be careful next time round. |
This guy is blind, wanna accuse me when he never even read properly, i have posted ealier that my S/L is at 95c. and i advise ppl to exit if dip below 95c. i believe most true memeber would know but i just cant help it but to suan this useless fool back. just 1 out or 3 prediction is correct still wanna wayang here. lol rofl.
Bro Beng, its quite obvious that there are people who will post nonsense just for the fun of it. Most likely, they (or is it he/she?), is some pock marked, obese person with no friends who spends all their time in front of the pc. Dont engage them.
For others who really have lost money just because of one or two days of bad market sentiment , dont come here and cow peh, cow pu. I have no sympatheties for you whatsoever. Lose money after one, two days, cry for what. Win money, do you pay anyone here?
Back to main topic. Mr Investor, if I may add two other facts:
a. this is a US$5 billion industry - ANNUALLY.
b. BIG has a 5% stake in Xtent and Devax.
